The third quarter reflected continued operational momentum, increased financial performance from individual pharmacy locations, driven by higher revenues, improved margins, better operating efficiencies, and disciplined progress on the Corporation's national acquisition strategy. Following quarter-end, PharmaCorp completed the acquisitions of 3 pharmacies, 2 located in Western Canada and 1 located in Eastern Canada, building further scale and reinforcing the platform's coast-to-coast ambitions.
Q3 2025 Financial Highlights
Revenues are driven by continuous increases in prescription volumes and front-of-store sales
Same-store sales, a supplementary financial measure, increased 9.4% year-over-year compared to Q3 2024, reflecting continued organic growth across our pharmacy network
Prescription volumes continue to grow, with total script count rising 7.2% year-over-year compared to Q3 2024, demonstrating sustained patient engagement and activity across the network
Operating infrastructure was successfully deployed to support national scalability, including systems integration, pharmacy onboarding, and co-ownership execution
Net loss for the quarter reflects continued investment in corporate infrastructure, stock options granted to directors and officers on July 18, 2025, as well as one-time legal fees to obtain our credit facility with CIBC
Solid pharmacy-level contribution margins and a disciplined weighted average EBITDA multiples across acquisitions support PharmaCorp's long-term accretive growth model
Management Commentary"We're encouraged by the strong performance of our initial acquisitions and by the ongoing interest from independent pharmacy owners considering their succession options," said Alan Simpson, Executive Chairman of PharmaCorp. "This quarter demonstrates steady progress in scaling the business through disciplined, methodical execution. We remain committed to maintaining a disciplined weighted average EBITDA multiple across transactions, reinforcing our objective of achieving accretive growth."
Operational UpdateDuring the quarter, the Corporation made key investments in systems, personnel, and integration processes necessary to support scalable national growth. The reported net loss includes options which were granted to directors and officers on July 18, 2025, and one-time legal fees to obtain our credit facility with CIBC.
Subsequent EventsOn October 2, 2025, PharmaCorp announced that it purchased a 100% interest in two pharmacies located in Western Canada, one of which includes the associated land and building. The aggregate purchase price for the 100% interest was $3,400,000 and was funded from cash and shares.
On October 2, 2025, PharmaCorp announced that it purchased a 100% interest in a pharmacy located in Eastern Canada. The aggregate purchase price for the 100% interest was $5,300,000 and was funded from cash and ...
